Enhanced percutaneous delivery of recombinant human epidermal growth factor employing nano-liposome system

Jeon, Sang-Ok; Hwang, Heejin; Oh, Dong-Ho; Seo, Jeong-Sun; Chun, Kyeung-Hwa; Hong, Sun-Mi; Kim, Min-Ju; Kim, Won-Chul; Park, Minsun; Yoon, Chae-Ha; Kim, Youn Hwan; Suh, Changwoo; Lee, Sang Kil

doi:10.3109/02652048.2011.646327

Cited by 28 publications

(18 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example in lung cancer, the deposition patterns of cisplatin aerosol therapy in surgically resected stage II lymph nodes was analyzed using hyperspectral imaging [100]. Hyperspectral imaging was also used to analyze the morphology and particle distribution of liposomes encapsulating recombinant human epidermal growth factor [101]. This type of imaging has also been utilized in patients for rapid histological classification of lung cancer type [102].…”

Section: Setup For Experimental Evaluationmentioning

confidence: 99%

Evaluation of uptake and distribution of gold nanoparticles in solid tumors

2015

View full text Add to dashboard Cite

Although nanotherapeutics offer a targeted and potentially less toxic alternative to systemic chemotherapy in cancer treatment, nanotherapeutic transport is typically hindered by abnormal characteristics of tumor tissue. Once nanoparticles targeted to tumor cells arrive in the circulation of tumor vasculature, they must extravasate from irregular vessels and diffuse through the tissue to ideally reach all malignant cells in cytotoxic concentrations. The enhanced permeability and retention effect can be leveraged to promote extravasation of appropriately sized particles from tumor vasculature; however, therapeutic success remains elusive partly due to inadequate intra-tumoral transport promoting heterogeneous nanoparticle uptake and distribution. Irregular tumor vasculature not only hinders particle transport but also sustains hypoxic tissue kregions with quiescent cells, which may be unaffected by cycle-dependent chemotherapeutics released from nanoparticles and thus regrow tumor tissue following nanotherapy. Furthermore, a large proportion of systemically injected nanoparticles may become sequestered by the reticuloendothelial system, resulting in overall diminished efficacy. We review recent work evaluating the uptake and distribution of gold nanoparticles in pre-clinical tumor models, with the goal to help improve nanotherapy outcomes. We also examine the potential role of novel layered gold nanoparticles designed to address some of these critical issues, assessing their uptake and transport in cancerous tissue.

show abstract

Section: Setup For Experimental Evaluationmentioning

confidence: 99%

Evaluation of uptake and distribution of gold nanoparticles in solid tumors

2015

View full text Add to dashboard Cite

show abstract

“…The emerging strategies for the transdermal delivery of peptide and protein drugs are summarized in an extensive review by Schuetz et al40 Several delivery systems have been proposed to serve as optimal carriers for the percutaneous delivery of growth factors;41 however, their efficacy under in vivo conditions remains to be confirmed.…”

Section: Routes Of Administrationmentioning

confidence: 99%

Biologics: the role of delivery systems in improved therapy

Škalko‐Basnet¹

2014

BTT

View full text Add to dashboard Cite

The beginning of the 21st century saw numerous protein and peptide therapeuticals both on the market and entering the final stages of clinical studies. They represent a new category of biologically originated drugs termed biologics or biologicals. Their main advantages over conventional drugs can be summarized by their high selectivity and potent therapeutic efficacy coupled with limited side effects. In addition, they exhibit more predictable behavior under in vivo conditions. However, up to now most of the formulations of biologics are designed and destined for the parenteral route of administration. As a consequence, many suffer from short plasma half-lives, resulting in their frequent administration and ultimately poor patient compliance. This review represents an attempt to address some of the challenges and promises in the product development of biologics both for parenteral and noninvasive administration. Some of the products currently in the pipeline of pharmaceutical development and corresponding perspectives are discussed in more detail.

show abstract

“…Another problem is side effects such as phlebitis or tissue necrosis due to repeated injection. Thus, potential alternative delivery methods via nasal, vaginal, rectal, oral, transdermal, and buccal routes have been considered in order to find solution [2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%